AMA
Shulga O, Chabanova A, Kotsiuba O. Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2023;32(1):23-30. doi:10.5114/ppn.2023.126319.
APA
Shulga, O., Chabanova, A., & Kotsiuba, O. (2023). Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 32(1), 23-30. https://doi.org/10.5114/ppn.2023.126319
Chicago
Shulga, Olga, Anna Chabanova, and Oleksandra Kotsiuba. 2023. "Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis". Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii 32 (1): 23-30. doi:10.5114/ppn.2023.126319.
Harvard
Shulga, O., Chabanova, A., and Kotsiuba, O. (2023). Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 32(1), pp.23-30. https://doi.org/10.5114/ppn.2023.126319
MLA
Shulga, Olga et al. "Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis." Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, vol. 32, no. 1, 2023, pp. 23-30. doi:10.5114/ppn.2023.126319.
Vancouver
Shulga O, Chabanova A, Kotsiuba O. Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2023;32(1):23-30. doi:10.5114/ppn.2023.126319.
